Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
59 60 Next >
Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
These two companies pay market-beating dividends to shareholders. 
Via The Motley Fool
7 Very Undervalued Penny Stocks to Buy in April 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option. 
Via InvestorPlace
AstraZeneca PLC (NASDAQ: AZN) Climbs to New 52-Week High
Via Investor Brand Network
Check Out What Whales Are Doing With AZN
Via Benzinga
Astrazeneca Plc (NASDAQ: AZN) Highlighted for Surprising Price Action
Via Investor Brand Network
A Look Into AstraZeneca Inc's Price Over Earnings
Via Benzinga
A Look Into AstraZeneca's Debt
Via Benzinga
AstraZeneca Unusual Options Activity
Via Benzinga
2 Steady Stocks to Buy and Hold Forever
Investing in these companies can help you sleep easy at night. 
Via The Motley Fool
Medical Behemoth AstraZeneca Flirts With Breakout On Fresh Hope In Ovarian Cancer
A combination of four drugs improved outcomes in ovarian cancer treatment. 
Via Investor's Business Daily
AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study
Via Benzinga
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many... 
Via Benzinga
7 Growth Stocks That Pay Generous Dividends
With these seven dividend-paying growth stocks, steady payouts plus underlying growth could produce strong long-term total returns. 
Via InvestorPlace
Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively
Via Benzinga
P/E Ratio Insights for AstraZeneca
Via Benzinga
A Look Into AstraZeneca's Debt
Via Benzinga
AstraZeneca Axes Pneumonia Drug Pact With Aridis
AstraZeneca plc (NASDAQ: AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS). 
Via Benzinga
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
Via Benzinga
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
From AstraZeneca
Via Business Wire
7 Blue-Chip Stocks to Buy for Capital Preservation
These are the low-beta blue-chip stocks to buy as they represent companies with a strong balance sheet and healthy cash flow potential. 
Via InvestorPlace
3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030
These historically profitable dividend-paying stocks are ideal for risk-averse investors wanting to take advantage of a bear market discount. 
Via The Motley Fool
Nvidia Ramps Up Artificial Intelligence Offerings Amid AI's 'iPhone Moment'
Nvidia on Tuesday demonstrated how its technology is advancing artificial intelligence in myriad industries. Nvidia stock has soared in 2023. 
Via Investor's Business Daily
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D... 
Via Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival... 
Via FinancialNewsMedia
Exposures Product Safety
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
Via Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
Via Benzinga
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.